Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q3 2015 · 10-Q
Revenue$17.70M$17.70Mno prior Q3 2014 on file Net Income$199.17M$199.17Mno prior Q3 2014 on file EPS Diluted$9.28$9.28no prior Q3 2014 on file Operating Income$8,597,000— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$10,437,000— Margins · derivedOperating margin48.6%
Net margin1125.2%
ended Sep 30, 2015 · filed Nov 9, 2015 · 40 d after period end